Poxel

Developing Innovative Drugs for Metabolic Diseases

Lyon, France · Founded 2009

Headquarters
Lyon
Employees
11–50
Founded
2009
Business Model
B2B
Last Round
Series BDec 2012
Rounds
2

About

Poxel is a clinical-stage biopharmaceutical company developing innovative treatments for chronic and rare diseases with metabolic pathophysiology. Founded in 2009 as a spin-off from Merck Serono in Lyon, France, the company focuses on non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. Its lead programs include PXL065 (NASH), PXL770 (rare diseases including ALD and ADPKD), and Imeglimin (Twymeeg), a first-in-class treatment for type 2 diabetes approved in Japan in 2021 and commercialized by partner Sumitomo Pharma across Asia. Poxel's AMPK-activator and deuterium-modified thiazolidinedione (dTZD) platforms target mitochondrial dysfunction and cellular energy metabolism.

Summary

Poxel is a Biotech company based in Lyon, France, founded in 2009. Its most recent funding was a Series B round in Dec 2012. Investors include Edmond de Rothschild Investment Partners and Omnes Capital.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BDec 2012

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Poxel on Indexed.vc
<a href="https://indexed.vc/companies/poxel"><img src="https://indexed.vc/api/badge/company/poxel" alt="Poxel on Indexed.vc" width="260" height="76" /></a>